JP2010006705A - Ｈｅｒ２サブセット - Google Patents

Ｈｅｒ２サブセット Download PDF

Info

Publication number
JP2010006705A
JP2010006705A JP2008155676A JP2008155676A JP2010006705A JP 2010006705 A JP2010006705 A JP 2010006705A JP 2008155676 A JP2008155676 A JP 2008155676A JP 2008155676 A JP2008155676 A JP 2008155676A JP 2010006705 A JP2010006705 A JP 2010006705A
Authority
JP
Japan
Prior art keywords
cancer
affinity ligand
her2
seq
subset
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2008155676A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010006705A5 (https=
Inventor
Mathias Uhlen
マティアス・ウーレン
Johan Rockberg
ヨハン・ロックバリィ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Atlas Antibodies AB
Original Assignee
Atlas Antibodies AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Atlas Antibodies AB filed Critical Atlas Antibodies AB
Priority to JP2008155676A priority Critical patent/JP2010006705A/ja
Priority to KR1020107027939A priority patent/KR20110036534A/ko
Priority to US12/997,823 priority patent/US20110158988A1/en
Priority to PCT/SE2008/000694 priority patent/WO2009151356A1/en
Priority to EP08874636A priority patent/EP2294088A1/en
Priority to CN2008801297639A priority patent/CN102099376A/zh
Priority to CA2727941A priority patent/CA2727941A1/en
Priority to AU2008357729A priority patent/AU2008357729A1/en
Priority to KR1020127017264A priority patent/KR20130026418A/ko
Publication of JP2010006705A publication Critical patent/JP2010006705A/ja
Publication of JP2010006705A5 publication Critical patent/JP2010006705A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2008155676A 2008-06-13 2008-06-13 Ｈｅｒ２サブセット Pending JP2010006705A (ja)

Priority Applications (9)

Application Number Priority Date Filing Date Title
JP2008155676A JP2010006705A (ja) 2008-06-13 2008-06-13 Ｈｅｒ２サブセット
KR1020107027939A KR20110036534A (ko) 2008-06-13 2008-12-12 Ｈｅｒ2 의 세포외 도메인 2 및 3 에 대한 항체
US12/997,823 US20110158988A1 (en) 2008-06-13 2008-12-12 Antibodies against extracellular domains 2 and 3 or her2
PCT/SE2008/000694 WO2009151356A1 (en) 2008-06-13 2008-12-12 Antibodies against extracellular domains 2 and 3 or her2
EP08874636A EP2294088A1 (en) 2008-06-13 2008-12-12 Antibodies against extracellular domains 2 and 3 or her2
CN2008801297639A CN102099376A (zh) 2008-06-13 2008-12-12 针对her2的细胞外结构域2和3的抗体
CA2727941A CA2727941A1 (en) 2008-06-13 2008-12-12 Antibodies against extracellular domains 2 and 3 or her2
AU2008357729A AU2008357729A1 (en) 2008-06-13 2008-12-12 Antibodies against extracellular domain 2 and 3 of HER2
KR1020127017264A KR20130026418A (ko) 2008-06-13 2008-12-12 Ｈｅｒ2 의 세포외 도메인 2 및 3 에 대한 항체

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2008155676A JP2010006705A (ja) 2008-06-13 2008-06-13 Ｈｅｒ２サブセット

Publications (2)

Publication Number Publication Date
JP2010006705A true JP2010006705A (ja) 2010-01-14
JP2010006705A5 JP2010006705A5 (https=) 2011-07-21

Family

ID=40427661

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008155676A Pending JP2010006705A (ja) 2008-06-13 2008-06-13 Ｈｅｒ２サブセット

Country Status (8)

Country Link
US (1) US20110158988A1 (https=)
EP (1) EP2294088A1 (https=)
JP (1) JP2010006705A (https=)
KR (2) KR20110036534A (https=)
CN (1) CN102099376A (https=)
AU (1) AU2008357729A1 (https=)
CA (1) CA2727941A1 (https=)
WO (1) WO2009151356A1 (https=)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013529904A (ja) * 2010-05-27 2013-07-25 ゲンマブ エー／エス Ｈｅｒ２に対するモノクローナル抗体
JP2013534809A (ja) * 2010-05-27 2013-09-09 ゲンマブ エー／エス Ｈｅｒ２エピトープに対するモノクローナル抗体
KR101759209B1 (ko) 2010-01-22 2017-07-19 성균관대학교산학협력단 Ｈｅｒ－２ 과발현 유방암 세포 또는 조직에 특이적으로 결합할 수 있는 핵산 압타머 및 그 용도
JP2021509288A (ja) * 2017-11-14 2021-03-25 グリーン クロス ラボ セル コーポレーションＧｒｅｅｎ Ｃｒｏｓｓ Ｌａｂ Ｃｅｌｌ Ｃｏｒｐｏｒａｔｉｏｎ 抗−ｈｅｒ２抗体又はその抗原結合フラグメント、及びこれを含むキメラ抗原受容体
US11649294B2 (en) 2017-11-14 2023-05-16 GC Cell Corporation Anti-HER2 antibody or antigen-binding fragment thereof, and chimeric antigen receptor comprising same
US12435118B2 (en) 2016-12-28 2025-10-07 GC Cell Corporation Chimeric antigen receptor and natural killer cells expressing same

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8609095B2 (en) 2010-03-04 2013-12-17 Symphogen A/S Anti-HER2 antibodies and compositions
AU2016201799B2 (en) * 2010-05-27 2017-09-07 Genmab A/S Monoclonal antibodies aganst HER2 epitope
AU2012245116A1 (en) 2011-04-20 2013-11-07 Genmab A/S Bispecific antibodies against HER2 and CD3
CN105017425B (zh) * 2014-04-30 2018-02-16 京天成生物技术(北京)有限公司 抗her2中和活性单克隆抗体及其应用
US20210346484A1 (en) * 2017-12-11 2021-11-11 Medizinische Universitaet Wien Method of producing a vaccine composition and uses thereof
US12172108B2 (en) 2018-08-16 2024-12-24 Emd Millipore Corporation Closed bioprocessing device
EP3842460A1 (en) * 2019-03-01 2021-06-30 RemeGen Co., Ltd. Antibody for her2 concomitant diagnosis immunohistochemical detection and application thereof

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5726023A (en) * 1993-03-17 1998-03-10 University Of Washington Immune reactivity to HER-2/neu protein for diagnosis and treatment of malignancies in which the HER-2/neu oncogene is associated
WO2001041787A1 (en) * 1999-12-10 2001-06-14 Epimmune Inc. INDUCING CELLULAR IMMUNE RESPONSES TO HER2/neu USING PEPTIDE AND NUCLEIC ACID COMPOSITIONS
US20030027766A1 (en) * 1995-03-14 2003-02-06 Board Of Regents, The University Of Texas System Methods and compositions for stimulating T-lymphocytes
WO2004052917A2 (en) * 2002-12-10 2004-06-24 Epimmune Inc. Hla-a1, a2 -a3,-a24,-b7,and -b44 tumor associated antigen peptides and compositions
WO2006007398A1 (en) * 2004-06-16 2006-01-19 Genentech, Inc. Therapy of platinum-resistant cancer
WO2007118660A2 (en) * 2006-04-13 2007-10-25 Bio Life Science Forschungs- Und Entwicklungsges M.B.H. Her-2/neu multi-peptide vaccine
WO2007146959A2 (en) * 2006-06-12 2007-12-21 Receptor Biologix Inc. Pan-cell surface receptor- specific therapeutics

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5783404A (en) * 1995-04-13 1998-07-21 Amgen Inc. Methods and compositions for determining HER-2/neu expression using monoclonal antibodies
CA2450793A1 (en) * 2001-06-20 2002-12-27 Prochon Biotech Ltd. Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof
CN1136917C (zh) * 2001-10-10 2004-02-04 北京迪威华宇生物技术有限公司 一种卡介苗热休克蛋白65和多表位her-2抗原融合蛋白重组蛋白疫苗
US7767792B2 (en) * 2004-02-20 2010-08-03 Ludwig Institute For Cancer Research Ltd. Antibodies to EGF receptor epitope peptides
DK1771482T3 (da) * 2004-07-22 2014-10-20 Genentech Inc HER2-antistofsammensætning
CN101165068B (zh) * 2006-10-18 2011-09-21 上海复旦张江生物医药股份有限公司 抗HER2/ErbB2抗原的单克隆抗体及其制备方法和药物组合物

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5726023A (en) * 1993-03-17 1998-03-10 University Of Washington Immune reactivity to HER-2/neu protein for diagnosis and treatment of malignancies in which the HER-2/neu oncogene is associated
US20030027766A1 (en) * 1995-03-14 2003-02-06 Board Of Regents, The University Of Texas System Methods and compositions for stimulating T-lymphocytes
WO2001041787A1 (en) * 1999-12-10 2001-06-14 Epimmune Inc. INDUCING CELLULAR IMMUNE RESPONSES TO HER2/neu USING PEPTIDE AND NUCLEIC ACID COMPOSITIONS
WO2004052917A2 (en) * 2002-12-10 2004-06-24 Epimmune Inc. Hla-a1, a2 -a3,-a24,-b7,and -b44 tumor associated antigen peptides and compositions
WO2006007398A1 (en) * 2004-06-16 2006-01-19 Genentech, Inc. Therapy of platinum-resistant cancer
WO2007118660A2 (en) * 2006-04-13 2007-10-25 Bio Life Science Forschungs- Und Entwicklungsges M.B.H. Her-2/neu multi-peptide vaccine
WO2007146959A2 (en) * 2006-06-12 2007-12-21 Receptor Biologix Inc. Pan-cell surface receptor- specific therapeutics

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101759209B1 (ko) 2010-01-22 2017-07-19 성균관대학교산학협력단 Ｈｅｒ－２ 과발현 유방암 세포 또는 조직에 특이적으로 결합할 수 있는 핵산 압타머 및 그 용도
JP2013529904A (ja) * 2010-05-27 2013-07-25 ゲンマブ エー／エス Ｈｅｒ２に対するモノクローナル抗体
JP2013534809A (ja) * 2010-05-27 2013-09-09 ゲンマブ エー／エス Ｈｅｒ２エピトープに対するモノクローナル抗体
JP2017038599A (ja) * 2010-05-27 2017-02-23 ゲンマブ エー／エス Ｈｅｒ２に対するモノクローナル抗体
JP2017046694A (ja) * 2010-05-27 2017-03-09 ゲンマブ エー／エス Ｈｅｒ２エピトープに対するモノクローナル抗体
US12435118B2 (en) 2016-12-28 2025-10-07 GC Cell Corporation Chimeric antigen receptor and natural killer cells expressing same
JP2021509288A (ja) * 2017-11-14 2021-03-25 グリーン クロス ラボ セル コーポレーションＧｒｅｅｎ Ｃｒｏｓｓ Ｌａｂ Ｃｅｌｌ Ｃｏｒｐｏｒａｔｉｏｎ 抗−ｈｅｒ２抗体又はその抗原結合フラグメント、及びこれを含むキメラ抗原受容体
US11649294B2 (en) 2017-11-14 2023-05-16 GC Cell Corporation Anti-HER2 antibody or antigen-binding fragment thereof, and chimeric antigen receptor comprising same
JP7386796B2 (ja) 2017-11-14 2023-11-27 グリーン クロス ラボ セル コーポレーション 抗－ｈｅｒ２抗体又はその抗原結合フラグメント、及びこれを含むキメラ抗原受容体
US11970547B2 (en) 2017-11-14 2024-04-30 GC Cell Corporation Anti-HER2 antibody or antigen-binding fragment thereof, and chimeric antigen receptor comprising same
US12116417B2 (en) 2017-11-14 2024-10-15 GC Cell Corporation Anti-HER2 antibody or antigen-binding fragment thereof, and chimeric antigen receptor comprising same
US12410261B2 (en) 2017-11-14 2025-09-09 GC Cell Corporation Anti-HER2 antibody or antigen-binding fragment thereof, and chimeric antigen receptor comprising same

Also Published As

Publication number Publication date
AU2008357729A8 (en) 2011-02-03
KR20110036534A (ko) 2011-04-07
WO2009151356A1 (en) 2009-12-17
CA2727941A1 (en) 2009-12-17
US20110158988A1 (en) 2011-06-30
AU2008357729A1 (en) 2009-12-17
KR20130026418A (ko) 2013-03-13
EP2294088A1 (en) 2011-03-16
CN102099376A (zh) 2011-06-15

Similar Documents

Publication Publication Date Title
JP2010006705A (ja) Ｈｅｒ２サブセット
DK2494359T3 (en) PODXL protein in colorectal cancer
US10793633B2 (en) Therapeutic peptides
EP3912998A2 (en) Binding molecules that inhibit cancer growth
TW201713684A (zh) 用於對抗食道癌及其他癌症的新穎胜肽及胜肽的組合物
KR20180026758A (ko) 식도암 및 기타 암에 대한 면역요법에 사용하기 위한 펩티드 및 펩티드의 조합
KR20140107615A (ko) 엑소좀 검출용 모노클로날 항체
EP2396346B1 (en) Rbm3 protein in colorectal cancer prognostics
AU2018274932A1 (en) Cancer cell-specific antibody, anticancer drug and cancer testing method
EP3541423A1 (en) Engineered antibodies and uses thereof
EP3558359A1 (en) Immunocytokines with progressive activation mechanism
US9416176B2 (en) RBM3 protein in colorectal cancer prognostics
CN112823168A (zh) 结合her2的四聚体多肽
CN110036110A (zh) 针对fzd10的单克隆抗体及其用途
HK40051469A (en) Her2-binding tetrameric polypeptides
성준식 Development and Characterization of Monoclonal Antibody Specific to Oncogenic Variant AIMP2-DX2
BR122025017078A2 (pt) Moléculas de ligação que inibem o crescimento do câncer

Legal Events

Date Code Title Description
A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20110223

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20110223

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110519

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20110519

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130205

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130502

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130510

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20130730